The overarching goal of the Cancer Biology Program, CBP, is to increase our understanding of the basic genetic, molecular, and biological mechanisms of cancer development and progression and to facilitate the translation of these findings for improved diagnostic, therapeutic, and preventative measures. The CBP consists of 51 Research Members, 14 Clinical Members, and 2 Adjunct Members. The membership spans 14 departments, and 2 centers, with two members from other institutions. The membership has $4.5 million in NCI funded research support out of a total of $30.6 million in total research support. The CBP program is highly productive with a total of 685 publications with 15% of the publications being intra-programmatic and 19% inter-programmatic. The program has been subdivided into 4 interdependent themes: Computational Biology, Functional Genomics, Cell Signaling, and Translation. The Computational Theme uses bioinformatic analyses of genomic, transcriptomic, proteomic, and metabolomic data to identify clinically relevant pathways for the development of therapeutic reagents or potential biomarkers to be moved to preclinical validation studies. The Functional Genomics Theme uses genetically engineered mouse models and patient-derived xenograft analysis to determine the significance of genetic alterations in human cancer as identified by the Computational Biology Theme. The Cell Signaling Theme functions to conduct in vitro mechanistic analysis of signaling pathways identified by the Computational and Functional Genomics Theme to determine how these pathways regulate cancer initiation, progression, and metastasis. The role of this group is to identify which pathways are targets for biomarkers or therapeutic development. Finally, the Translational Theme consists of clinical researchers and researchers involved in development of novel therapeutics. The goal of this Theme is to facilitate the translation of the basic science findings of the CBP to the patient. This group aids CBP researchers in determining how these findings can be translated to the development of therapies and biomarkers for the treatment of cancer.

Public Health Relevance

Dan L. Duncan Cancer Center at Baylor College of Medicine OVERALL - PROJECT NARRATIVE Cancer is a leading cause of morbidity and mortality in the United States and globally. The diagnosis and treatment of cancer are extraordinarily demanding and increasingly expensive with major impacts on our economy. Although overall survival from cancer has improved and certain cancers can be prevented or cured, much remains to be accomplished to improve patient outcome through research to develop novel strategies to prevent, diagnose early, and effectively treat this disease. The Dan L. Duncan Cancer Center at Baylor College of Medicine has put together a strong multidisciplinary team of scientists, clinicians, educators, and community outreach experts to further improve survival from cancer both in our Catchment Area and globally, and to educate the scientists and clinicians of the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA125123-10S4
Application #
9338792
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Shafik, Hasnaa
Project Start
2007-07-01
Project End
2020-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
10
Fiscal Year
2016
Total Cost
$499,947
Indirect Cost
$135,790
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
Badr, Hoda; Herbert, Krista; Bonnen, Mark D et al. (2018) Dyadic Coping in Patients Undergoing Radiotherapy for Head and Neck Cancer and Their Spouses. Front Psychol 9:1780
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Gates, Leah A; Gu, Guowei; Chen, Yue et al. (2018) Proteomic profiling identifies key coactivators utilized by mutant ER? proteins as potential new therapeutic targets. Oncogene 37:4581-4598
Ballester, Leomar Y; Lu, Guangrong; Zorofchian, Soheil et al. (2018) Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors. Acta Neuropathol Commun 6:85
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Qin, Liying; Sankaran, Banumathi; Aminzai, Sahar et al. (2018) Structural basis for selective inhibition of human PKG I? by the balanol-like compound N46. J Biol Chem 293:10985-10992
Shi, Xiangguo; Kitano, Ayumi; Jiang, Yajian et al. (2018) Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells. Exp Hematol 64:33-44.e5
Disney-Hogg, Linden; Cornish, Alex J; Sud, Amit et al. (2018) Impact of atopy on risk of glioma: a Mendelian randomisation study. BMC Med 16:42

Showing the most recent 10 out of 991 publications